Shares in Teva Pharmaceuticals (NYSE:TEVA) climbed 12% this morning after the company announced it plans to cut more than a quarter of its global workforce, suspend its dividend and shut down research facilities and factories.
The drug-maker, which appointed a new CEO and management team this year, is looking to restructure and pay down debt.
Get the full story at our sister site, Drug Delivery Business News.
The post Teva to slash 14,000 jobs in restructuring effort appeared first on MassDevice.